Skip to main
SLDB

Solid Biosciences (SLDB) Stock Forecast & Price Target

Solid Biosciences (SLDB) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Solid Biosciences is well positioned for success with their strong data package, unique safety profile, and potential approval from the FDA. The company may also benefit from changes in FDA leadership and has a promising pipeline for other genetic cardiac and neuromuscular diseases. With a market currently undervaluing the potential success of their treatments, Solid Biosciences's stock shows potential for growth and differentiation in the market.

Bears say

Solid Biosciences is currently focused on developing gene therapy treatments for neuromuscular and cardiac diseases. While the company has had some promising results in biomarker data, there are concerns about potential safety issues and the company's ability to successfully bring these treatments to market given the changing leadership at the FDA and the stringent regulatory requirements. Additionally, there is a significant financing risk as the company may need to seek partnerships or additional funding to support future commercialization and product development. Overall, the stock's current valuation appears to be discounting a lower probability of success, but if the upcoming functional data is positive, there could be significant upside potential.

Solid Biosciences (SLDB) has been analyzed by 12 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Solid Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Solid Biosciences (SLDB) Forecast

Analysts have given Solid Biosciences (SLDB) a Buy based on their latest research and market trends.

According to 12 analysts, Solid Biosciences (SLDB) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Solid Biosciences (SLDB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.